Instructions for Credit —This activity is accredited for 1.0 continuing education credit for nurse practitioners, nurses, and social workers. Participants must attend the free webinar in its entirety, submit the online evaluation form and complete and submit the online post-test with a passing score of 70% to earn credit. Once submitted, the certificate will be automatically generated as a PDF online.
Please retain a copy of the certificate for your records. For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at (609) 333-1693 or ndane@mlicme.org.
You must be enrolled to complete this activity for credit, however, you are not required to enroll simply to view the presentation.
Target Audience — Nurse practitioners, nurses and oncology social workers involved in the care of patients with myelodysplastic syndromes (MDS).
Course Content Level for Social Workers — Intermediate and Advanced
Format: noninteractive recorded webinar
| Learning Objectives — At the conclusion of this program, participants will be able to: | |
| • | Describe the various types and subtypes of MDS |
| • | Identify tests used to diagnose disease and monitor treatment of MDS |
| • | Explain the overarching goals of treatment for the types of MDS |
| • | Explain approved and emerging treatment options for MDS, including stem cell transplantation, and the role of clinical trials |
| • | Describe the roles of the pharmacist, the nurse and the social worker in treating patients with MDS |
Provider — This activity is provided by The Leukemia & Lymphoma Society.
Continuing Education for Nurse Practitioners, Nurses, and Social Workers
Nurse Practitioner Credit Designation
This activity is approved for 1.0 contact hour of continuing education (which includes .75 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20064277. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hours through the California Board of Registered Nursing.
Social Worker Designation
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. LLS maintains responsibility for this course. ACE provider approval period: 12/10/17-12/14/2020. Social workers completing this course receive 1.0 continuing education credits.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for this program. Social workers will receive 1.0 CE clinical contact hours for this activity.
To view system requirements please go to https://llsce.org/system-requirements
For questions, grievances, or assistance with special needs (physical, etc.) please contact us at infocenter@LLS.org.
Disclosure of Conflicts of Interest — All faculty participating in continuing education activities by The Leukemia & Lymphoma Society are expected to disclose to activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) discussed in their presentations.
Faculty Disclosures
Sangmin Lee, MD, Consulting fees from: AstraZeneca and Helsinn.
Peter Campbell, PharmD, BCOP, has no financial disclosures.
Ayelet Nelson, RN, LMSW, ANP-BC, has no financial disclosures.
Content/Peer Reviewer Disclosure
Rookmini Singh, MSN, has no financial disclosures.
Disclaimer –Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| Estimated time to complete activity: 1.0 hours |
| Date of initial release: May 20, 2020 |
| Expiration of: June 30, 2021 |
 |
|
Sangmin Lee, MD, is an Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at the NewYork-Presbyterian Hospital.
After obtaining a BA/MS as a Vagelos Scholar in Molecular Life Sciences at the University of Pennsylvania in 2003, Dr. Lee received his MD from the University of Miami in 2007. Following his internal medicine residency at the University of Alabama at Birmingham, he completed his fellowship in hematology and oncology at the New York Presbyterian Hospital/Columbia University Medical Center from 2010-2013 where he focused on epigenetics of myelodysplastic syndromes (MDS) under Drs. Azra Raza and Benjamin Tycko. In July 2013, Dr. Lee was recruited to serve in the Leukemia Program in the Division of Hematology & Medical Oncology. At Weill Cornell, he has served as an Edward P. Evans Fellow in the multi-institutional MDS Clinical Research Consortium, focusing on development of clinical and translational research programs in MDS, as well as other hematologic malignancies. He is currently the principal investigator on clinical trials investigating new therapeutic approaches in elderly AML patients, and is an investigator on a number of clinical trials for MDS, AML, and other myeloproliferative neoplams. He is the principal investigator for translational studies focusing on characterization of mutational and epigenetic profiling of MDS and AML, in collaboration with scientists at Weill Cornell Medicine.
Dr. Lee has publications in the Clinical Cancer Research, and Journal of Blood Medicine, among others. He is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Association for Cancer Research.
 |
|
Peter Campbell, PharmD, BCOP, is a Clinical Pharmacy Manager at Columbia University Irving Medical Center in New York, New York. Dr. Campbell is a Board-Certified Oncology Pharmacist, and his area of specialized clinical practice is in acute and chronic leukemias, with a primary practice site of the inpatient setting. Dr. Campbell is also the Program Director for the PGY2 oncology pharmacy residency at New York-Presbyterian Hospital.
Dr. Campbell graduated from St. John’s University College of Pharmacy and Allied Health Professions in Queens, New York. He then completed a pharmacy practice residency followed by an oncology pharmacy specialty residency at New York-Presbyterian Hospital.
 |
|
Ayelet Nelson, MSW, ANP-BC, is a Leukemia Outpatient Nurse Practitioner at Weill Cornell Medicine in New York, New York, where she monitors and treats patients with hematologic malignancies utilizing both standard treatments as well as innovative treatments administered as part of clinical trials. Ms. Nelson earned her Masters of Social Work at the New York University Silver School of Social Work in New York, New York, and continued her education by completing the Adult Nurse Practitioner Master’s Program at the Boston College Connell School of Nursing in Chestnut Hill, Massachusetts. She is passionate about working with each patient as an individual to address his or her unique needs throughout the journey of a cancer diagnosis while providing compassionate care. She has also helped to initiate a support group for young adult patients with leukemia.
Resources for HCPs
Online & In-person free CME & CE courses: www.LLS.org/CE
Treating Blood Cancers podcasts: www.LLS.org/HCPpodcast
Clinical Trials and Research
- Clinical Trials: Learn more about clinical trials: LLS.org/ClinicalTrials
- Research: Focused on finding cures, driving research in areas of unmet medical need, and bridging the gap between academic discovery & drug development: LLS.org/Research
Advocacy dedicated to removing barriers to care: www.LLS.org/Advocacy
Resources for Patients
MDS Specific Resources – www.LLS.org/MDS
Free Information Booklets: www.LLS.org/Booklets
Telephone/Web Education Programs: www.LLS.org/Programs
Videos: www.LLS.org/Educationvideos
Podcasts: www.LLS.org/LLS-podcast
Support Resources : www.LLS.org/Support
- Financial Assistance
- Co-Pay
- Travel Assistance
- Referral to Medication Access programs
- Information Resource Center
- LLS Chapters
- LLS Community (social media platform)
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- One-On-One Nutrition Consultations (PearlPoint)
Information Resource Specialists: www.LLS.org/IRC
Assist through treatment, financial & social challenges, and give accurate treatment and support information. HCPs can also order free materials to distribute to patients.
Clinical Trial Support Center: www.LLS.org/CTSC
Patients & caregivers work one-on-one with an LLS Clinical Trial Nurse Navigator who will help find clinical trials and personally assist throughout the clinical trial process, providing an additional resource to the HCP team
- Phone: (800) 955-4572, M-F, 9 am to 9 pm ET
- Email: infocenter@LLS.org
Live chat: www.LLS.org/InformationSpecialists
If you have any questions, please contact us at ProfEducation@LLS.org or call our Information Resource staff at 800-955-4572